Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...

Five months ago, J&J also revealed its plan to spend $2 billion over the next 10 years to operate a 160,000-square-foot ...

As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U.S.

Early launch numbers of Brinsupri are so strong that Insmed couldn’t wait for the J.P. Morgan Healthcare Conference to share ...

After a turbulent 2025, the biopharma industry is heading into the new year with major questions still unresolved. | In this ...

Listening to patients is no longer a “nice to have” for life sciences companies—it is a strategic necessity that can ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

With a lioness-themed rebrand tied to its latest buy, Athira Pharma is roaring into the new year under its second new moniker.  | The LeonaBio rebrand comes from the name Leona, which means lioness ...

As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house ...

Less than two weeks ago, Vanda scored an FDA approval for motion sickness pill, Nereus. The decision came 15 months after the ...

In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring AbbVie, AstraZeneca, ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...